Core Viewpoint - The company plans to increase the estimated amount of daily related party transactions for 2025 due to business development needs, ensuring that this will not affect its independence or reliance on related parties [1][2]. Group 1: Increase in Related Party Transactions - The company intends to increase the estimated amount of daily related party transactions for 2025 from 500 million RMB to 6.9 billion RMB, primarily due to new product demands from a related party, Guorun Medical Supply Chain Service (Shanghai) Co., Ltd [1]. - The increase in related party transactions has been approved by the board of directors and does not require shareholder meeting approval [1]. Group 2: Related Party Information - Guorun Medical Supply Chain Service (Shanghai) Co., Ltd is a subsidiary of a company in which the company holds shares, and it specializes in providing comprehensive services for medical laboratories [1]. - As of December 31, 2024, Guorun Supply Chain had total assets of 2.44 billion RMB and net assets of 734.38 million RMB, with an annual revenue of 1.00 billion RMB [1]. Group 3: Transaction Purpose and Impact - The related party transactions are necessary for the company's normal business operations and are conducted on fair and voluntary terms, ensuring no harm to the interests of the company or its shareholders [2]. - The pricing policy for these transactions is based on market fair prices, and they do not significantly impact the company's assets or profit situation [2].

Core Viewpoint - The company plans to temporarily use idle raised funds not exceeding 160 million yuan to supplement working capital for a period not exceeding 12 months, approved by the board of directors [1][4]. Summary by Sections 1. Basic Situation of Raised Funds - The company has been approved to publicly issue convertible bonds totaling 550 million yuan, with a net amount received of approximately 537.91 million yuan after deducting underwriting fees and other expenses [1]. 2. Temporary Use of Idle Raised Funds - The company intends to use up to 160 million yuan of idle raised funds to temporarily supplement working capital, primarily for activities related to its main business [2][3]. - The balance of the raised funds in the storage account as of June 9, 2025, is approximately 197.97 million yuan [2]. 3. Compliance and Approval Process - The use of idle funds complies with relevant laws and regulations, ensuring that it does not affect the normal progress of the investment projects funded by the raised capital [3][4]. - The board and supervisory committee have approved the proposal, confirming that the decision-making process adheres to regulatory requirements [4][5]. 4. Opinions from Supervisory Committee and Sponsor - The supervisory committee believes that the temporary use of idle funds will enhance capital efficiency and support the development of the company's main business without harming shareholder interests [4]. - The sponsor, Guojin Securities, has no objections to the company's plan, confirming that all necessary approval procedures have been followed [4].

国金证券股份有限公司 关于上海润达医疗科技股份有限公司 使用闲置募集资金暂时补充流动资金的核查意见 国金证券股份有限公司（以下简称"本保荐机构"）作为上海润达医疗科技股 份有限公司（以下简称"润达医疗"、"公司"）公开发行可转换公司债券的保荐机 构，根据《证券发行上市保荐业务管理办法》、 《上海证券交易所上市公司自律监 管指引第 12 号——可转换公司债券》等相关规定，对润达医疗不提前赎回"润达 转债"事项进行了认真、审慎的核查。核查的具体情况如下： 一、募集资金基本情况 公司《公开发行可转换公司债券募集说明书》披露的募集资金项目以及截至 拟使用募集资金金额 已累计投资金额 序号 项目 | | | 经中国证券监督管理委员会《关于核准上海润达医疗科技股份有限公司公开 发行可转换公司债券的批复》（证监许可【2020】586 号）核准，同意润达医疗 向社会公开发行面值总额 55,000.00 万元可转换公司债券，期限 6 年，共计募集 资金 550,000,000.00 元，扣除承销费用 9,900,000.00 元（不含增值税）后实际收 到的金额为 540,100,000.00 元，上述款项已由主承销商国金证券股 ...

国金证券股份有限公司 | 序号 | 项目 | 拟使用募集资金金额 | 已累计投资金额 | | --- | --- | --- | --- | | | | （万元） | （万元） | | 1 | 综合服务扩容项目 | 55,000.00 | 34,115.38 | | | 合计 | 55,000.00 | 34,115.38 | 关于上海润达医疗科技股份有限公司 使用闲置募集资金暂时补充流动资金的核查意见 国金证券股份有限公司（以下简称"本保荐机构"）作为上海润达医疗科技股 份有限公司（以下简称"润达医疗"、"公司"）公开发行可转换公司债券的保荐机 构，根据《证券发行上市保荐业务管理办法》、《上海证券交易所上市公司自律监 管指引第 12 号——可转换公司债券》等相关规定，对润达医疗不提前赎回"润达 转债"事项进行了认真、审慎的核查。核查的具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准上海润达医疗科技股份有限公司公开 发行可转换公司债券的批复》（证监许可【2020】586 号）核准，同意润达医疗 向社会公开发行面值总额 55,000.00 万元可转换公司债券，期限 6 年，共计募集 资金 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-030 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 2024 年 12 月 4 日，公司第五届董事会第十九次会议审议通过了《关于公司 2025 年度日常关联交易预计的议案》。关联董事张诚栩、刘辉、胡震宁、陆晓 艳已回避表决。 上海润达医疗科技股份有限公司 关于增加 2025 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因公司业务发展的需要，依据实际情况，增加与关联方2025年度日常关 联交易预计的金额。 本次日常关联交易不会导致公司对关联方形成依赖，不会影响上市公司 的独立性。 本次增加的日常关联交易金额在公司董事会审批范围之内，无需提交股 东大会审议。 一、增加日常关联交易履行的审议程序 2024年12月20日，2024年第三次临时股东大会审议通过了《关于公司2025 年度日常关联交易预计的议案》。关联股东已回避表决。 2025年6月13日 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-029 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 使用闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次使用闲置募集资金暂时补充流动资金的金额不超过 16,000 万元； ●使用期限：自公司董事会审议批准之日起不超过 12 个月。 公司于 2025 年 6 月 13 日召开了第五届董事会第二十三次会议和第五届监事 会第十六次会议审议通过了《关于使用闲置募集资金暂时补充流动资金的议案》， 同意公司使用闲置募集资金不超过 16,000 万元暂时补充流动资金，使用期限自 董事会审议批准之日起不超过 12 个月。现将相关事宜公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准上海润达医疗科技股份有限公司公开 发行可转换公司债券的批复》（证监许可【2020】586号）核准，同意上海润达 医疗科技股 ...

本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规和公司章程的规定，会议及通过的决议合 法有效。 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-028 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海润达医疗科技股份有限公司（以下简称"公司"）第五届董事会第二十 三次会议通知于 2025 年 6 月 10 日以邮件形式发出，会议于 2025 年 6 月 13 日（星 期五）10:00-11:00 在上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼公司会议室以 现场及通讯相结合的方式召开。会议应到董事 11 人，实到董事 11 人（其中董事 姚沈杰、周晓兰、何嘉、冯国富因工作等原因以通讯方式参会），公司监事严晨、 吴伟钟、丁秋泉和高级管理人员廖上林列席了会议。会议由 ...

Core Viewpoint - The rapid development of the private equity investment sector has led to A-share listed companies engaging in various forms of private equity investments to discover and incubate quality targets within their industry and supply chains, while also expanding their investment paths. CVC funds led by listed companies have become a crucial force in the private equity market, but they face scrutiny due to potential conflicts of interest and regulatory restrictions, particularly after the implementation of the "Private Investment Fund Registration and Filing Measures" on May 1, 2023 [1][14]. Pathways for Establishing Private Fund Managers - A total of 16 private fund managers related to A-share listed companies have been approved by the Asset Management Association of China (AMAC) from May 1, 2023, to May 1, 2025. These include 1 wholly-owned subsidiary, 4 controlled by listed companies, 10 directly or indirectly invested by listed companies, and 1 established by the actual controller of a listed company [2]. Pathway One: Wholly Owned Establishment - Listed companies can establish private fund managers wholly owned by themselves. This pathway is subject to strict regulatory scrutiny due to the potential classification as "quasi-financial" businesses [3][6]. Pathway Two: Controlling Establishment - Listed companies can also establish controlling private fund managers where they hold more than 50% of the shares. However, this pathway has seen limited success due to regulatory concerns, with only 4 such managers registered since the new regulations [3][4]. Pathway Three: Joint Establishment with Third Parties - This pathway involves listed companies partnering with third parties to establish private fund managers, where the listed company acts as a financial or strategic investor. This has proven to be a more viable option, with 10 managers established under this model since the new regulations [4][5]. Pathway Four: Establishment by Actual Controllers - Actual controllers of listed companies can establish private fund managers directly. This pathway is less restricted, provided that the listed company does not directly invest in the fund manager [6][10]. Compliance Points for Each Pathway - Pathways one and two face stricter regulatory requirements due to the direct control by listed companies, necessitating good financial health and adherence to internal decision-making and disclosure procedures [7][8]. - Pathway three requires careful attention to the legitimacy of the investment purpose and compliance with disclosure obligations, especially regarding related party transactions [10][11]. - Pathway four mandates that the actual controller disclose their relationship with the fund manager and comply with related party transaction regulations if the listed company invests in the fund [12][13]. Risk Prevention Measures - Listed companies and their affiliates must be vigilant against risks such as insider trading, conflicts of interest, and the misuse of non-public information. Establishing robust internal controls and compliance mechanisms is essential to mitigate these risks [12][13]. Conclusion - The article summarizes four pathways for listed companies to establish private fund managers, highlighting the regulatory landscape and compliance requirements. The core controversy revolves around the "quasi-financial" risks associated with these activities, emphasizing the need for a balance between industrial investment demands and financial regulatory boundaries. Future policies may exhibit flexibility, recognizing the value of supporting the real economy while preventing unchecked capital expansion [14].

Group 1 - The company has returned all idle raised funds amounting to 180 million yuan to its special account for raised funds, as approved by the board of directors [1][2] - The funds were temporarily used to supplement the company's liquidity for a period not exceeding 12 months [1] - The company has notified the sponsor institution, Guojin Securities Co., Ltd., regarding the return of the funds [1] Group 2 - The company will begin paying interest on its convertible bonds, "Run Da Convertible Bonds," starting from June 17, 2025, for the period from June 17, 2024, to June 16, 2025 [3][4] - The interest payment amount for each bond with a face value of 100 yuan will be 1.80 yuan (including tax) [11][14] - The bond's interest rate for the fifth year is set at 1.8% [11][14] Group 3 - The bond's record date for interest payment is June 16, 2025, and the ex-dividend date is June 17, 2025 [5][15] - The total issuance scale of the convertible bonds is 550 million yuan, with a total of 5.5 million bonds issued [6] - The initial conversion price of the bonds has been adjusted to 13.00 yuan per share as of July 19, 2024, due to profit distribution [10]

上海润达医疗科技股份有限公司（以下简称"公司"）于2024年6月27日召开 了第五届董事会第十四次会议和第五届监事会第十次会议审议通过了《关于使用 闲置募集资金暂时补充流动资金的议案》，同意公司使用闲置募集资金不超过 18,000万元暂时补充流动资金，使用期限自董事会审议批准之日起不超过12个月。 有关详情见公司于2024年6月28日披露的《使用闲置募集资金暂时补充流动资金 的公告》（公告编号：临2024-029）。 截至本公告披露日，公司已将上述用于临时补充公司流动资金的募集资金 18,000万元全部归还至公司募集资金专用账户，并将上述募集资金的归还情况通 知了保荐机构国金证券股份有限公司及保荐代表人。 特此公告。 2025 年 6 月 9 日 关于归还用于暂时补充流动资金的闲置募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海润达医疗科技股份有限公司 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-026 | | --- | --- | --- | | 转债代码：11358 ...